Product
Tetravalent influenza virus lysis vaccine
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
Clinical Study on Immunogenicity and Safety of Recombinant Novel Coronavirus（COVID-19）Vaccine (CHO Cell) Combined With Tetravalent Influenza Virus Lysis Vaccine in People Aged 18 Years and OverStatus: Completed, Estimated PCD: 2022-03-04